Preterm Birth and PROM Testing Market (By Test Type: Preterm Birth Tests [Pelvic Exam, Ultrasound, Uterine Monitoring, Biomarkers], PROM Tests [Nitrazine Test, Ferning Test, Pooling, Ultrasound, Fetal Fibronectin Test, Biomarker Tests, Others; By End-user: Hospitals, Diagnostic Laboratories, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026
Select Access Type
Introduction
The global market size of preterm birth and PROM testing was value at 1.11 billion at 2017 and is expected to reach 1.31 billion by the end of year 2026. The market is estimated to grow at a CAGR of 1.74% over the forecast period.
Market Dynamics
Premature rupture of membranes (PROM) is one of the main cause of preterm births. Increment in a number of preterm births because of ascending in normal time of ladies being pregnant and different wellbeing concerns, for instance, diabetes and hypertension among ladies drive the worldwide preterm birth and prom testing market. Also, increment sought after for point-of-care testing gadgets and ascend popular for cost-effective symptomatic tests are the key variables driving the global market growth. On the other hand, the absence of awareness about new advancements for the diagnosis of preterm births and utilization of substitutes of diagnostic options, for instance, lab tests, transvaginal examine, ultrasound, uterine observing etc., may hamper the target market growth. The rise in the number of preterm births, ascend in the quantity of claim to fame facilities, high rate of preterm births, and simple discovery of preterm birth through PROM tests are some factors expected to grow the global market. The preterm birth tests segment is projected to dominate the worldwide preterm birth and PROM testing market. Conversely, the accessibility of different tests in the market is expected to hamper the growth of the target market.
Market Insights
Traditional options for preterm birth testing incorporate sterile speculum examination (pooling), pelvic examination, blood test, ultrasound, and fetal fibronectin (fFN) test. To examine preterm labor, specialists analyze side effects, for instance, pelvic weight, vaginal spotting or dying, issues or normal withdrawals, vaginal release, and liquid spillage. A pelvic test is played out various time for a couple of hours to observe constrictions and identify changes in the cervix. Pelvic examination is the mainline test led by specialists to quantify the adjustments in the cervix. This segment is estimated to contribute around US$ 200.0 Mn in revenue to the worldwide preterm birth and PROM testing market by the end of 2025.
PROM testing techniques comprises of nitrazine and ferning test, ultrasound, biomarker tests, for instance, Placental alpha microglobulin-1 (PAMG-1), Insulin-like development factor restricting protein 1 (IGFBP-1), and Alpha-fetoprotein (AFP) test. Conventional options, for instance, nitrazine and ferning tests are quickly being followed by improved biochemical marker detection packs. Clinical investigations recommend that PAMG-1 based tests give improved indicative exactness and affectability contrasted with conventional tests for identification of premature rupture of membranes. The aforesaid factors are projected to feed the market growth in terms of revenue, by the end of the year 2026.
Consistently, around 5 mn children around the globe are conceived before the 37th week of pregnancy and the number is required to increment further. Around 1 mn kids kick the bucket every year because of difficulties brought about by preterm births. Premature Rupture of Membranes (PROM) causes about 4.5 million preterm births every year, around the world. Preterm birth is among the most common reasons for death among neonates within the primary month of their life. The most normally utilized way for the assurance of preterm birth is using biomarkers. PROM tests, such as, ultrasound, biomarkers, and fetal fibronectin tests are generally led in medical clinics and centers to decide the event of PROM.
Market Segmentation
Market Segmentation, By Test Type:
- Preterm Birth Tests
- Pelvic Exam
- Ultrasound
- Uterine Monitoring
- Biomarkers
- PROM Tests
- Nitrazine Test
- Ferning Test
- Pooling
- Ultrasound
- Fetal Fibronectin Test
- Biomarker Tests
- Others
- Market Segmentation, By End-user:
- Hospitals
- Diagnostic Laboratories
- Others
Market Segmentation, By Region:
- North America
- Europe
- Asia Pacific
- Central & South America
- Middle East & Africa
Regional Insights
In the North America market, around 3.9 Mn children are conceived every year, of which 12.0% are brought into the world premature. In the Europe region, Germany has one of the most elevated preterm birth rates with 9.0% of 670,000 yearly births being preterm. As per the March of Dimes, a nonprofit association concentrated on improving maternal and baby wellbeing, the premature birth rate in the U.S. has expanded for the third back to back year in 2018, and the nation is among the most developed countries as far as premature births. Such factors exhibit the requirement for improvement of exceptionally precise yet cost-effective strategies for a finding of premature rupture of membranes.
Market Participants
Major companies contributing the global preterm birth and PROM testing market are Qiagen, Hologic, Cooper Surgical, Abbott Laboratories, Medixbiochemica, Sera Prognostics, Biosynex, and IQ Products.